Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15496606 | 1.00 | NR1I2 (0.55) | NR1I2ALBPDE4D | |
| SCHEMBL15975550 | 0.86 | PGK1 (0.53) | PDE4D | |
| SCHEMBL15975256 | 0.86 | PGK1 (0.53) | PDE4D | |
| SCHEMBL15499076 | 0.86 | LMNA (0.55) | ALBPDE4D | |
| SCHEMBL15496601 | 0.86 | LMNA (0.55) | ALBPDE4D | |
| SCHEMBL15975549 | 0.85 | ADORA3 (0.44) | ALBPDE4D | |
| SCHEMBL15496605 | 0.85 | PGK1 (0.45) | ALBPDE4D | |
| SCHEMBL15975543 | 0.85 | PGK1 (0.45) | ALBPDE4D | |
| SCHEMBL15975265 | 0.85 | ADORA3 (0.44) | ALBPDE4D | |
| SCHEMBL15975264 | 0.85 | ADORA3 (0.44) | ALBPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815829-B2 | 3′-azido purine nucleotide prodrugs for treatment of viral infections | RFS PHARMA, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | NR1I2 660/4885ALB 1912/4885PDE4D 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.